CD274 and neoplasm: In patients with unresectable locally advanced, metastatic, or recurrent TNBC who have not previously received systemic therapy, SKB-264 with or without KL-A167 (a PD-L1 inhibitor) is being tested in the phase II clinical trial known as NCT05445908 to determine its safety, tolerability, and anti-tumor efficacy.